• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

    3/11/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care
    Get the next $INBS alert in real time by email

    NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the iAccess Alpha Virtual Best Ideas Spring Conference 2025 on March 25 and 26, 2025.

    iAccess Alpha Virtual Conference Details:

    Date: March 25-26, 2025

    Presentation Day and Time: Tuesday, March 25th at 11:00 a.m. ET

    Webcast: https://www.webcaster4.com/Webcast/Page/3083/52118

    INBS will also conduct one-on-one meetings during the conference. To schedule a meeting with management, please contact your representatives at iAccess or email KCSA Strategic Communications at [email protected].

    About Intelligent Bio Solutions Inc. 

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

    For more information, visit: http://www.ibs.inc/

    Company Contact:   

    Intelligent Bio Solutions Inc.  

    [email protected]   

    LinkedIn | Twitter 

    Investor & Media Contact:  

    Valter Pinto, Managing Director  

    KCSA Strategic Communications  

    PH: (212) 896-1254  

    [email protected]



    Primary Logo

    Get the next $INBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

      SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

      11/14/24 7:16:17 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

      SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

      11/14/24 4:31:30 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing

      NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced recent growth highlights across its global operations, driven by new account acquisitions, expansion into new testing areas and sectors, and continued penetration into safety-critical industries. The Company's total number of active accounts has surpassed 450, with 35 new accounts added in fiscal Q3 alone. INBS' Intelligent Fingerprinting Drug Screening System, which detects recent drug use in under ten minutes through fingerprint sweat analysis, continues to gain tra

      5/15/25 9:00:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

      20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a st

      5/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show

      NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation as a gold sponsor at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference and Trade Show, taking place from April 1 – 4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions, will present at the International Symposium on Tuesday, April 1, at 1:00 PM. Daniel will introduce the Company's Intelligent Fingerprinting Drug Testing Solution, a portable, non-invasive solution designed to enable

      3/28/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    SEC Filings

    See more
    • Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/16/25 8:00:18 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/13/25 5:15:23 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Intelligent Bio Solutions Inc.

      10-Q - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/13/25 8:35:51 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Financials

    Live finance-specific insights

    See more
    • Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

      20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a st

      5/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements

      Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six

      2/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

      - Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update. Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared to the same period the prior year, and full-year revenue totalled $3.11 million,

      9/19/24 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

      4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      3/31/25 4:15:27 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Simeonidis Harry was granted 40,000 shares, increasing direct ownership by 9,804% to 40,408 units (SEC Form 4)

      4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      9/27/24 5:00:16 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

      4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      9/27/24 5:00:15 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care